• Recruiting

RADAR (UK-MRA Myeloma XV): treatment escalation and de-escalation strategies in NDMM - TE Myeloma

Updated: Oct 23

RADAR (UK-MRA Myeloma XV): Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).

RADAR (UK-MRA Myeloma XV)

RADAR (UK-MRA Myeloma XV): Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).


EudraCT Number: 2019-001258-25

National Competent Authority: UK - MHRA


Full title of the trial

Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).


Name of Sponsor

University of Leeds

Cancer Research UK

Sanofi (isatuximab) and Celgene (lenalidomide)

Sanofi S.A

Celgene Corporation

 

RADAR (UK-MRA Myeloma XV)

EudraCT Number: 2019-001258-25

A phase II and phase III trial comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplant (TE)

Date on which this record was first entered in the EudraCT database: 2020-03-18

Click here for details

 

https://www.ukmf.org.uk/

https://www.ukmf.org.uk/wp-content/uploads/2020/11/RP-UKMF21_Trials-update.pdf

 

Treatment Agents | Myeloma Clinical Trials (themyelomaclinicaltrials.com)

 

Locations

Europe

United Kingdom

Posts Archive